Azevan Pharmaceuticals, Inc., is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. The company’s first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of major depression, intermittent explosive disorder, impulse control/anger disorders, and post-traumatic stress disorder (PTSD). Vasopressin receptor antagonists represent a novel mechanism of action for addressing these indications.
Location: China
Employees: 1-10
Investors 2
| Date | Name | Website |
| - | Ben Frankl... | nep.benfra... |
| - | Life Scien... | lsgpa.com |
Mentions in press and media 2
| Date | Title | Description |
| 18.10.2013 | To advance treatment for post traumatic stress disorder, biotechnology firm raises $2.2M | The company is housed at Ben Franklin Tech Ventures on Lehigh University’s campus, which is part of Ben Franklin Technology Partners of Northeastern Pennsylvania. Ben Franklin is part of the state’s economic development arm. Other Tech Vent... |
| - | To advance treatment for post traumatic stress disorder, biotechnology firm raises $2.2M | Mood and behavior disorders, such as post traumatic stress and depression, affect up to 40 million in the U.S. A biotechnology company developing a way to treat the disorders has raised $2.2 million, according to a Form D filing with the U.... |